Journal: bioRxiv
Article Title: Pharmacodynamic and stage-dependent therapeutic efficacy of SFRP1 neutralization in a mouse model of Alzheimer’s disease
doi: 10.64898/2026.03.26.714543
Figure Lengend Snippet: ( A ) Schematic of the experimental design. 4-month-old homozygous APP/PS1 mice received weekly retro-orbital injections of IgG1 or α-SFRP1.10 (100 µg) for 5 months; analyses in panels ( B–G ) were performed at 9 months of age. The time diagram indicates the expected age at which these mice initiate amyloid-β plaque accumulation. Illustration from NIAID NIH BioArt Source ( https://bioart.niaid.nih.gov/ ). ( B ) ELISA quantification of SFRP1 levels in brain RIPA-soluble homogenates. ( C ) Representative confocal images of cortices (top) and hippocampi (bottom) from IgG1-treated (left) and α-SFRP1.10-treated (right) mice stained with Thioflavin S (ThioS) to label amyloid plaque cores. Scale bar: 100 µm. Quantification of the number (top) and mean plaque area (bottom) of ( D ) ThioS+ plaques and ( E ) LAMP1-positive puncta in the cortex (left) and hippocampus (right). Quantification of (F) GFAP and (G) Iba1 fluorescence intensity in the cortex (left) and hippocampus (right), expressed as fold change relative to the mean value of the IgG1 group. Quantification analyses were performed for individual mice, averaging the results of 3-8 slices per mouse. Data are presented as mean ± SEM. Statistical analyses were performed using Student’s t test.
Article Snippet: The reaction was terminated by adding 2N HCl (100 μl/well), and the resulting product was measured at 450 nm in a microtiter plate ELISA reads FLUOstar OPTIMA (BMG Lab Tech, Germany).
Techniques: Enzyme-linked Immunosorbent Assay, Staining, Fluorescence